






TABLE 5

NEWLY FDA-APPROVED ANTICANCER THERAPEUTICS: AUGUST 1, 2018-JULY 31, 2019

| APPROVED INDICATION | GENERIC NAME | TRADE NAME | |
|---|----------------------------|------------|---|
| Angiogenesis Inhibitors | | | |
| Certain type of liver cancer [†] | cabozantinib | Cabometyx |  |
| Certain type of liver cancer [†] | lenvatinib | Lenvima |  |
| Certain type of liver cancer [†] | ramucirumab | Cyramza |  |
| Antinutrients | | | |
| Certain type of leukemia | calaspargase pegol-mknl | Asparlas |  |
| Cell-cytoskeleton Modifying Agents | | | |
| Certain type of non-Hodgkin lymphoma | polatuzumab vedotin-piiq | Polivy |  |
| Cell-death Promoting Agent | | | |
| Certain type of leukemia [†] | venetoclax | Venclexta |  |
| Cell-signaling Inhibitors | | | |
| Certain type of breast cancer | alpelisib* | Piqray |  |
| Certain type of lung cancer | dacomitinib* | Vizimpro |  |
| Certain types of leukemia and non-Hodgkin lymphoma | duvelisib | Copiktra |  |
| Certain type of bladder cancer | erdafatinib* | Balversa |  |
| Certain type of leukemia | glasdegib | Daurismo |  |
| Certain type of leukemia | gilteritinib* | Xospata |  |
| NTRK-positive solid tumors | larotrectinib | Vitrakvi |  |
| Certain type of lung cancer | lorlatinib* | Lobrena |  |
| Cell Lysis Mediators | | | |
| Certain types of non-Hodgkin lymphoma | mogamulizumab-kpkc | Poteligeo |  |
| Certain type of leukemia | tagraxofusp-erzs | Elzonris |  |
| DNA-damaging Agent | | | |
| Certain types of stomach cancer [†] | trifluridine AND tipiracil | Lonsurf |  |
| DNA-repair Inhibitors | | | |
| Certain type of breast cancer | talazoparib* | Talzenna |  |
| Hormones/Antihormones | | | |
| Prostate cancer | darolutamide | Nubeqa |  |
| Immune-checkpoint Inhibitors | | | |
| Certain type of breast ^{†*} and lung [†] cancers | atezolizumab | Tecentriq |  |
| Certain type of kidney cancer [†] | avelumab | Bavencio |  |
| Certain type of skin cancer | cemiplimab-rwlc | Libtayo |  |
| Certain type of lung cancer [†] | nivolumab | Opdivo |  |
| Certain types of esophageal ^{†*} , kidney, [†] liver, [†] and lung [†] cancer, and Merkel cell carcinoma [†] | pembrolizumab | Keytruda |  |
| Immune-system Modifier | | | |
| Certain types of non-Hodgkin lymphoma [†] | lenalidomide | Revlimid |  |
| Immunotoxins | | | |
| Certain type of leukemia | moxetumomab pasudotox-tdfk | Lumoxiti |  |
| Nuclear Export Inhibitors | | | |
| Multiple myeloma | selinexor | Xpovio |  |

[†]new cancer type approved 2018-2019

* requires a companion diagnostic